Elevance Health: Argus Research raises to buy from hold
ELV•Argus Research raised its rating on Elevance Health to buy from hold.
Related News

Bally's Corporation: Truist Securities cuts target price to $9 from $10
BALY•

Immix Biopharma cuts target price to $22 from $23
IMMX•

BellRing Brands names Travis Leonard CFO, succeeding Paul Rode
BRBR•

Nextpower: Mizuho raises target price to $104 from $98
NXT•

Immunome presents at Evercore and Piper Sandler healthcare conferences
IMNM•